Oncology company Azaya Therapeutics Inc. has announced the launch of a contract development and manufacturing organization (CDMO) that will provide chemical testing and liposomal manufacturing serices to outside organizations. Azaya is a company focused on utilizing its nanotechnology platform for developing more effective cancer treatments. Parexo Labs will use Azaya's twin capabilities in cytotoxic and nanoparticle analysis and liposome manufacturing, including its proprietary analytical methodology to detail release rates and characterization attributes of nanoparticles. Parexo Labs also offers laboratory services that can speed drug development and regulatory process for pharmaceutical and medical device developers. Read the full story.